

lesion #4:

nodular lesion at baseline
plaque by 4 wks


grade 2 erythema: wks 4 & 8
grade 1 at 2 & 12 wks
grade 0 erythema at 14 wks



lesion #5:

nodular lesion at baseline
plaque by 4 wks

grade 2 erythema: wks 4 & 8
grade 1 at 2 & 12 wks
grade 0 erythema at 14 wks




lesion #6:

nodular lesion at baseline
plaque by 4 wks

grade 2 erythema: wks 4 & 8

grade 1 at 2 & 12 wks

grade 0 erythema at 14 wks



SUMMARY of Patient

- Modified ACTG: PR
- Physician's global assessment: SD
- Satisfaction with the KS lesions treated: neutral
- Cosmetically beneficial response: NO

The next example of a panretin responder with a response that was not cosmetically beneficial is patient . This patient had 3 plaque lesions at baseline. One of these lesions became flat. All 6 lesions became nodular or a grade not specified in the CRF.

lesion #1:

plaque at baseline
flat at 4 wks
height grade "3" at 12 wks


grade 2 erythema at 4 wks
grade 3 erythema at 8 and 12 wks



lesion #2:

plaque at baseline
flat at 4 wks; plaque at 8 wks; grade 3 height at 12 wks

grade 2 erythema at 4 wks
grade 3 erythema at 8 and 12 wks




lesion #3:

plaque at baseline

grade 2 erythema at 4 wks

at 8 and 12 wks: grade 3 erythema and grade 3 height




lesion #4:

plaque at baseline


grade 2 erythema at 4 wks

grade 3 erythema: 8-14 wks




lesion #5:
flat at baseline

erythema




lesion #6:
flat at baseline

erythema



If one steps back from the index lesions of the patient, one has a better perspective of what is occurring in the patient. Here are global views of the legs of patient at baseline & 11 wks . The following index lesions are included: #3 (rt. calf), #4 (rt. thigh), & #6(left calf). By the erythema that is evident, note the non-index lesions that were treated with panretin.



SUMMARY of Patient

Modified ACTG criteria: PR

Physician's global assessment: SD

Patient satisfaction with the KS lesions treated: very satisfied

Cosmetically beneficial response: NO

APPEARS THIS WAY
ON ORIGINAL


EXAMPLES OF COSMETICALLY BENEFICIAL RESPONSES TO PLACEBO

The first example of a patient who did have a beneficial response to placebo is case . There were 3 plaque and 3 nodular lesions at baseline. By the modified ACTG criteria, a partial response was scored when all 6 of these lesions had height reductions. Also, note the acne in the photos starting between 4 -8 weeks; the patient was on anabolic steroids.


lesion #1:

plaque at baseline
flat at 20 wks


note acne in photos: pt has taking anabolic steroids




lesion #2:
 nodule at baseline
 plaque at 4 wks
 area 1/2 at 20 wks




lesion #3:
 nodule at baseline
 plaque at 2 wks
 gone at 16 wks



lesion #4:
 plaque at baseline
 flat at 8 wks
 gone at 16 wks




lesion #5
 plaque at baseline
 1/2 area at 8 wks
 gone at 16 wks



lesion #6
 nodule at baseline
 plaque at 2 wks
 gone at 8 wks

Note: crixivan started 1 wk before response started.



SUMMARY of Patient

- Modified ACTG criteria: PR
- Physician's global assessment: PR
- Patient satisfaction with the KS lesions treated: moderately satisfied
- Cosmetically beneficial response: YES

The next example of a patient who did have a beneficial response to placebo is patient . There were 3 plaque lesions at baseline. All of these became flat.